These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38696316)

  • 1. Erdafitinib (Balversa) for urothelial carcinoma.
    Med Lett Drugs Ther; 2024 May; 66(1702):e83-e84. PubMed ID: 38696316
    [No Abstract]   [Full Text] [Related]  

  • 2. Erdafitinib for advanced urothelial carcinoma.
    Burki TK
    Lancet Oncol; 2019 Sep; 20(9):e469. PubMed ID: 31378458
    [No Abstract]   [Full Text] [Related]  

  • 3. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
    Grülllich C
    Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
    [No Abstract]   [Full Text] [Related]  

  • 7. Erdafitinib: First Global Approval.
    Markham A
    Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
    Franza A; Pirovano M; Giannatempo P; Cosmai L
    Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
    Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
    Dosne AG; Valade E; Goeyvaerts N; De Porre P; Avadhani A; O'Hagan A; Li LY; Ouellet D; Perez Ruixo JJ
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):151-164. PubMed ID: 34977972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
    Siefker-Radtke AO; Loriot Y
    Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
    [No Abstract]   [Full Text] [Related]  

  • 13. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 14. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O'Hagan A; Avadhani A; Siefker-Radtke AO;
    N Engl J Med; 2019 Jul; 381(4):338-348. PubMed ID: 31340094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.
    Matsubara N; Miura Y; Nishiyama H; Taoka R; Kojima T; Shimizu N; Hwang J; Ote T; Oyama R; Toyoizumi K; Mukhopadhyay S; Triantos S; Deprince K; Loriot Y
    Int J Clin Oncol; 2024 Oct; 29(10):1516-1527. PubMed ID: 39017806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
    Nauseef JT; Villamar DM; Lebenthal J; Vlachostergios PJ; Tagawa ST
    Expert Opin Pharmacother; 2020 Jun; 21(8):863-870. PubMed ID: 32124650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erdafitinib for the treatment of urothelial cancer.
    Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
    [No Abstract]   [Full Text] [Related]  

  • 20. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
    Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
    Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.